Carr, Michael J. http://orcid.org/0000-0001-6233-4004
Monzon, Federico A.
Zager, Jonathan S. http://orcid.org/0000-0002-6886-4468
Article History
Received: 28 January 2021
Accepted: 20 March 2021
First Online: 8 June 2021
Declarations
:
: M.J.C. has no conflicts of interest to disclose. F.A.M. is a former employee and current stock option holder at Castle Biosciences, Inc. J.S.Z. has advisory board relationships with Novartis, Sanofi/Regeneron, Merck; receives research funding from Amgen, Delcath Systems, Philogen, Provectus; consults for Castle Biosciences and Philogen, speaker’s bureau for Castle Biosciences, Pfizer and SunPharma. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.